10 Clinical Research Excellence ICON and Employees Earn Prestigious Recognition
ICON plc a leading global healthcare intelligence and clinical research organization, has received multiple prestigious awards in the second half of 2024, further solidifying its position as a top performer…
Argenx Celebrates VYVDURA Approval in Japan for CIDP in Adults
Argenx SE a global immunology company dedicated to improving the lives of people affected by severe autoimmune diseases, has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has…
Colorectal Cancer Breakthrough Bristol Myers Squibb Secures EC Approval for Opdivo + Yervoy in MSI-High mCRC
Colorectal Cancer Breakthrough: Bristol Myers Squibb Secures EC Approval for Opdivo + Yervoy in MSI-High mCRC Bristol Myers Squibb has announced that the Colorectal Cancer European Commission (EC) has approved…
Bristol Myers Squibb Announces Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb has announced positive results from arthritis two pivotal Phase 3 trials, POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), which evaluated the efficacy and safety of Sotyktu (deucravacitinib)…
FDA Grants Groundbreaking Pioneering Approval for Opdivo Qvantig Injection in 5 Adult Solid Tumor Indications
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection for subcutaneous use. This innovative combination product…
Lilly Applauds ITC Ruling on Counterfeit Tirzepatide Imports 2024
In a significant victory for patient safety, the judge presiding over Eli Lilly’s case before the International Trade Commission (ITC) ruled that U.S. Customs and Border Protection should block the…
Aetna Launches Spanish Support for Health App to Serve Diverse Communities
Aetna , a CVS Health® company , has enhanced the functionality of its Aetna Health℠ app to offer Spanish language support for all eligible health plan members, regardless of their…
Regeneron Advances Factor XI Antibodies to Phase 3 After Positive Phase 2 Results
Regeneron Pharmaceuticals has announced positive Phase 2 results for two innovative monoclonal antibodies targeting distinct domains of Factor XI. REGN7508, designed to maximize anticoagulant activity while minimizing bleeding risk, targets…
Merck Invests €120M in Shizuoka Advanced Materials Center
Merck, a leading science and technology company, announced plans to invest over €70 million in constructing a new Advanced Materials Development Center (AMDC) at its Shizuoka site in Japan. This…
Roche Prasinezumab Shows Potential in Early Parkinson’s Despite Phase IIb Miss
Roche has announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 individuals with early-stage Parkinson’s disease. Participants received treatment for a minimum of 18 months while maintaining…
Merck Reports Phase 3 Results for DOR/ISL HIV Treatment
Merck known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of…
WHO Academy Launched by Marcron And World Health Organization Leaders
The World Health Organization WHO Academy in Lyon, France, officially opened its doors yesterday with a grand inauguration ceremony. The event was graced by French President Emmanuel Macron, WHO Director-General…